Journals / MN Oftalmoloji / 2000 / Cilt: 7 - Sayı: 1

Efficacy of long-term use of 1% vs timolol 0.5% in primary angle glaucoma and long-term drift

Primer açık açılı glokomda %1 carteolol ve %0.5 timololun uzun süreli kullanımının göziçi basıncına etkisi ve direnç gelişimi

Pages
27–30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: Carteolol 1% seems more effective than timolol 0.5% in lowering intraocular pressure through one year follow up measurements and it is effective on IOP when long term drift occured to timolol therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIMS: To evaluate efficacy of long -term use of carteolol 1% vs timolol 0.5% in primary angle glaucoma and to show possible long-term drift with these drugs.
📊
Key Findings & Data:Twenty-two patients received carteolol 1% twice a day for one year in Group 1.
💡
Conclusion & Impact:CONCLUSION: Carteolol 1% seems more effective than timolol 0.5% in lowering intraocular pressure through one year follow up measurements and it is effective on IOP when long term drift occured to timolol therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Zaman faktörleri · Timolol · Doz-yanıt ilişkisi

Abstract

AIMS: To evaluate efficacy of long -term use of carteolol 1% vs timolol 0.5% in primary angle glaucoma and to show possible long-term drift with these drugs. METHOD: Fourty-nine patients with primary open angle glaucoma were randomly divided in three groups for this prospective study. Twenty-two patients received carteolol 1% twice a day for one year in Group 1. Thirteen patients received timolol 0.5 % twice a day for one year in Group 2. Fourteen patients received timolol 0.5 % twice a day for first six months and than drug switched to carteolol 1% twice a day for last six months in Group 3. Initial intraocular pressures(IOP) and posttreatment one week; one, three, six months visits results in all groups and one year results of Group 1 and 2 were evaluated and compared statistically. RESULTS: After one year treatment, carteolol 1 % reduced the mean IOP from 24.77±0.87 to 17.41±1.22 mmHg; timolol 0.5 % reduced the mean IOP from 24.64±0.79 to 20.18±1.22 mmHg . While pretreatment IOPs were not significantly difference between Group 1 and 2 (p=0.25), at the end of one year there was statistically significant difference between them (p< 0.001). At the first six months treatment of Group 3, timolol 0.5% reduced the mean IOP from 25.32±1.29 to 20.14±1.12 mmHg (p< 0.001) but it showed long-term drift between one and three months. At the last six months carteolol 1% reduced the mean IOP from 20.14±1.12 mmHg to 17.04±0.7 mmHg (p< 0.001) without loss of effectiveness. CONCLUSION: Carteolol 1% seems more effective than timolol 0.5% in lowering intraocular pressure through one year follow up measurements and it is effective on IOP when long term drift occured to timolol therapy.

Özet

AMAÇ: Primer açık açılı glokomda %1 carteolol ve %0.5 timololün uzun süreli kullanımda etkinliğini ve direnç gelişimini araştırmak. YÖNTEM: Primer açık açılı glokomlu 49 olgu bu prospektif çalışmada randomize olarak 3 gruba ayrıldı. Grup fi oluşturan 22 olgu bir yıl boyunca günde iki kez %1 carteolol kullandı. Grup 2'deki 13 olgu bir yıl boyunca günde iki kez %0.5 timolol kullandı. Grup 3 teki 14 olgu ise ilk 6 ay günde iki kez %0.5 timolol, sonraki 6 ay ise günde iki kez %1 carteolol kullandı. Başlangıç göziçi basınçları (GİB) ve tedavi başlandıktan sonraki 1. hafta, 1, 3. ve 6. ay GİB ları her 3 grupta; 1 yıl GİB'ları ise ilk iki grupta ölçülerek istatistiksel olarak karşılaştırıldı. BULGULAR: Bir yıllık tedavi süresi sonunda %1 carteolol ortalama GİB'nı 24.77±0.87'den 17.41±1.22 mmHg'ya; %0.5 timolol ise ortalama GİB'nı 24.64±0.79'den 20.18±1.22 mmHg'ya düşürdü. Grup 1 ve 2 arasındaki ortalama başlangıç GİB'ları arasında anlamlı farklılık olmamasına rağmen (p=0.25), bir yıl sonundaki ölçümler arasındaki fark anlamlı idi (p< 0.001). Grup 3 te ilk 6 aylık tedavide %0.5 timolol ortalama GİB'nı 25.32±1.29 den 20.14±11.12 mmHg (p< 0.001 )ya düşürmesine rağmen 1. ve 3. aydaki ölçümlerde etkide azalma saptandı. Sonraki 6 aylık tedavide ise %1 carteolol ortalama GİB m etki kaybı olmadan 20.14±1.12 mmHg dan 17.04±0.7 mmHg (p< 0.001) ya düşürdü. SONUÇ: Uzun süreli kullanımda %1 carteololün %0.5 timololden daha etkili olduğu ve etki kaybının daha az olduğu, timolole direnç geliştiğinde de GİB'nı yeniden güvenli düzeylere düşürdüğü saptandı.

🔖

Cite This Article

YAŞAR, T., ÇİNAL, A., ÖZDEMİR, M. (2000). Efficacy of long-term use of 1% vs timolol 0.5% in primary angle glaucoma and long-term drift. MN Oftalmoloji, Cilt: 7 - Sayı: 1, 27–30. https://ajindex.com/articles/296389

References (17)

  1. Katz I. Beta-blockers and the eye. An overview. Ann Ophthaimol 1978; 10: 847-50
  2. Coakes RL, Brubaker RF. The mechanism of timolol in lawering intraocular pressure in the normal eye. Arch Ophthaimol 1978; 96: 2045-8
  3. Van Joost TH, Hup JM, Ros FE. Dermatitis as a side-effect of long-term topical treatment with certain beta-blockıng agents Br J Dermatol 1979; 101: 171-6
  4. Nathanson JA. Effects of a potent and specific fS2 -adrenoceptor antagonist on intraacular pressure. Br J Pharmacol 1981; 73 97-100
  5. Nathanson JA. ICI 118,551: An effective ocular hypotensive agent with seleetivity for the ciliary process fi2 - adrenoceptor and with minimal cardiac side effects. Br J Pharmacol 1984 83: 821-9
  6. Watanabe K, Chiou GC. Action mechanism of timolol to lower the intraocular pressure in rabbits. Ophthalmic Res 1983- 15' 160-7
  7. Trope GE, Clark B. Beta adrenergic receptors in pigmented cılıary processes. Br J Ophthaimol 1982; 66: 788-792
  8. Boger WP III, Puliafito CA, Steinert RF, Langston D. Long-term experience with timolol ophthalmic salution in patients with open-angle glaucoma. Ophthalmology 1979; 85:259-67
  9. Wilcockson J, Wilcockson T. Long-term timolol use in patients with chronic open-angle glaucoma: Results of a 40-month study. Glaucoma 1982; 4:155-8
  10. Sılverstone DE, Arkfeld D, Cowan G et al. Long-term diurnal control of intraocular pressure with levobunolol and with timolol. Glaucoma 1935; 7: 138-40
  11. Yıldırım N, Yurdakul S, Topbaş S, Özer A.Türe M, Ata N, Ardıç S. Primer açık açılı glokomda carteolol,timolol maleat ve betoxololun göziçi basıncına,kardiovasküler sisteme ve solunum fonksiyonlarına olan etkilerinin karşılaştırılması. T Oft Gaz 1991; 21, 287-93
  12. Zimmerman TJ, Canale P. Timolol-further observations. Ophthalmol 1979; 86: 166-9
  13. Boger WP. Timolol: Short term 'escape' and İong term 'drift'. Ann Ophthalmol 1979; 11:1239-42
  14. Boger WP, Steinert RF, Puliafito CA, Pavarı-Langstan DP, Clinical trial comparing timoiol ophthalmic solution to piiocarpine in open-angle glaucoma. Am J Ophthalmol 1978; 86: 8-18
  15. Steinert RF, Thomas JV, Boger WP. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol 1981; 99: 100-3
  16. Neufeld AH, Zawistowksi KA, Page ED, Bromberg BB. İnfluences on the density of beta adrenergic receptors in the cornea and iris-ciliary body of the rabbit. Invest Ophthalmoi Vis SCİ1978; 17: 1069-75
  17. Calissendorff BM, Maren N. Timoiol-maintenance treatment. Ac